Evidence map›Paper›PMID 37579104›Full record

ArticleJournal of addiction medicine

Long-Term Effects of Increasing Buprenorphine Treatment Seeking, Duration, and Capacity on Opioid Overdose Fatalities: A Model-based Analysis.

Erin J Stringfellow, Tse Yang Lim, Catherine DiGennaro, Ziyuan Zhang, Pritika Paramasivam, Benjamin Bearnot, Keith Humphreys, Mohammad S Jalali

Open access · greenAbstract read
In one paragraph

Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Erin J StringfellowFrom the Massachusetts General Hospital, Harvard Medical School, Boston, MA (EJS, ZZ, PP, MSJ); Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA (TYL, CD, MSJ); Harvard T.H. Chan School of Public Health, Boston, MA (TYL); Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA (BB); and Veterans Affairs and Stanford University Medical Centers, Palo Alto, CA (KH).
Tse Yang Lim
Catherine DiGennaro
Ziyuan Zhang
Pritika Paramasivam
Benjamin Bearnot
Keith Humphreys
Mohammad S Jalali
Harvard University · USMassachusetts General Hospital · USMassachusetts Institute of Technology · USMt. San Jacinto College · US

Funding

Expanding FDA's Opioids Systems Model to Enable Economic Evaluations and Outcome Analyses of National Opioid PoliciesU01FD007064 · FDA · MASSACHUSETTS GENERAL HOSPITAL · PI JALALI, MOHAMMAD S. · 2020 to 2021
$1.2M
FDA HHS U01 FD007064
6 · The paper itself

Abstract

objectivesBecause buprenorphine treatment of opioid use disorder reduces opioid overdose deaths (OODs), expanding access to care is an important policy and clinical care goal. Policymakers must choose within capacity limitations whether to expand the number of people with opioid use disorder who are treated or extend duration for existing patients. This inherent tradeoff could be made less acute with expanded buprenorphine treatment capacity.

methodsTo inform such decisions, we used a validated simulation model to project the effects of increasing buprenorphine treatment-seeking, average episode duration, and capacity (patients per provider) on OODs in the United States from 2023 to 2033, varying the start time to assess the effects of implementation delays.

resultsResults show that increasing treatment duration alone could cost lives in the short term by reducing capacity for new admissions yet save more lives in the long term than accomplished by only increasing treatment seeking. Increasing provider capacity had negligible effects. The most effective 2-policy combination was increasing capacity and duration simultaneously, which would reduce OODs up to 18.6% over a decade. By 2033, the greatest reduction in OODs (≥20%) was achieved when capacity was doubled and average duration reached 2 years, but only if the policy changes started in 2023. Delaying even a year diminishes the benefits. Treatment-seeking increases were equally beneficial whether they began in 2023 or 2025 but of only marginal benefit beyond what capacity and duration achieved.

conclusionsIf policymakers only target 2 policies to reduce OODs, they should be to increase capacity and duration, enacted quickly and aggressively.

Indexed as

BuprenorphineDrug OverdoseOpiate OverdoseOpioid-Related DisordersAnalgesics, OpioidHumansNarcotic AntagonistsOpiate Substitution TreatmentUnited StatesAnalgesics, OpioidBuprenorphineNarcotic Antagonists

Identifiers

PMID37579104
PMCPMC10460819
OpenAlexW4321163565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.